Olipudase alfa-rpcp


Olipudase alfa-rpcp

Latest News

loading GIF

Drug updated on 4/17/2024

Dosage FormInjection (intravenous; 20 mg)
Drug ClassHydrolytic lysosomal enzymes
Ongoing and
Completed Studies


  • Indicated for treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Xenpozyme (olipudase alfa-rpcp) prescribing information. 2023Genzyme Corporation, Cambridge, MA